The Frost & Sullivan Best Practices Awards recognize companies at the forefront of their industries that consistently demonstrate leadership in innovative solutions that meet ever-evolving customer needs and are superior in overall price, performance, and quality. WuXi AppTec was honored with this award for providing unmatched customer value by enabling healthcare innovation through cost-effective and efficient solutions. WuXi AppTec's unique CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development and Manufacturing Organization) business models offer end-to-end services for drug R&D and manufacturing, enabling its partners to advance discoveries and deliver groundbreaking treatments to patients more quickly.

"WuXi AppTec's one-of-a-kind business model stands out in the global healthcare industry," commented Ojaswi Rana, a research analyst at Frost & Sullivan. "With customer-centricity as a fundamental value proposition, WuXi AppTec is delivering high-quality services that lower the barriers to R&D and help advance innovation across different stages of the drug development process."

"We are honored to receive this award from Frost & Sullivan, and thank them for recognizing the value of our global platform to customers," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "Through our unique CRDMO and CTDMO business models, WuXi AppTec will continue to enhance our enabling platform and serve as a trusted partner to global customers who are driving healthcare advancements and delivering innovative new drugs to patients in need."